Array ( [0] => {{Short description|Medication to prevent nausea and vomiting}} [1] => {{Use dmy dates|date=February 2024}} [2] => {{Infobox drug [3] => | verifiedrevid = 477170896 [4] => | image = Ondansetron skeletal.svg [5] => | width = 225 [6] => | alt = [7] => | image2 = Ondansetron 3D.png [8] => | width2 = 250 [9] => | alt2 = [10] => | caption = [11] => [12] => [13] => | pronounce = [14] => | tradename = Zofran, Atossa,{{cite web | title= Atossa | website= MedicinesFAQ |year = 2022 | url = https://www.medicinesfaq.com/brand/atossa | access-date = 28 August 2022 |archive-url= https://web.archive.org/web/20220828171406/https://www.medicinesfaq.com/brand/atossa |archive-date= 28 August 2022 |url-status=live }}{{Unreliable source?|date=August 2022}} others [15] => | Drugs.com = {{drugs.com|monograph|ondansetron}} [16] => | MedlinePlus = a601209 [17] => | DailyMedID = Ondansetron [18] => | pregnancy_AU = B1 [19] => | pregnancy_AU_comment = {{cite web | title=Ondansetron Use During Pregnancy | website=Drugs.com | date=3 October 2019 | url=https://www.drugs.com/pregnancy/ondansetron.html | access-date=7 September 2020 | archive-date=18 September 2020 | archive-url=https://web.archive.org/web/20200918212204/https://www.drugs.com/pregnancy/ondansetron.html | url-status=live }} [20] => | pregnancy_category= [21] => | routes_of_administration = [[Oral administration|orally]] (by mouth), [[Rectal administration|rectal]], [[intravenous therapy|intravenous]], [[intramuscular injection|intramuscular]], [[Thin-film drug delivery|thin film]] [22] => | class = [23] => | ATC_prefix = A04 [24] => | ATC_suffix = AA01 [25] => | ATC_supplemental = [26] => [27] => [28] => | legal_AU = S4 [29] => | legal_AU_comment = {{cite web | title=Zofran Product and Consumer Medicine Information Licence | website=TGA eBS | url=http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-01055-1 | access-date=28 August 2022 | archive-date=29 August 2022 | archive-url=https://web.archive.org/web/20220829011623/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-01055-1 | url-status=live }} [30] => | legal_BR = [31] => | legal_BR_comment = [32] => | legal_CA = Rx-only [33] => | legal_CA_comment = {{cite web | title=Zofran Product information | website=Health Canada | date=25 April 2012 | url=https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43116 | access-date=28 August 2022 | archive-date=29 August 2022 | archive-url=https://web.archive.org/web/20220829011237/https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43116 | url-status=live }} [34] => | legal_DE = [35] => | legal_DE_comment = [36] => | legal_NZ = [37] => | legal_NZ_comment = [38] => | legal_UK = POM [39] => | legal_UK_comment = {{cite web | title=Zofran Tablets 4 mg - Summary of Product Characteristics (SmPC) | website=(emc) | date=19 January 2022 | url=https://www.medicines.org.uk/emc/product/195/smpc | access-date=28 August 2022 | archive-date=29 August 2022 | archive-url=https://web.archive.org/web/20220829011033/https://www.medicines.org.uk/emc/product/195/smpc | url-status=dead }} [40] => | legal_US = Rx-only [41] => | legal_US_comment = [42] => | legal_EU = Rx-only [43] => | legal_EU_comment = {{cite web|url=https://www.ema.europa.eu/documents/psusa/ondansetron-list-nationally-authorised-medicinal-products-psusa/00002217/202102_en.pdf|title=List of nationally authorised medicinal products : Active substance: ondansetron :Procedure no.: PSUSA/00002217/202102|website=Ema.europa.eu|access-date=5 March 2022}} [44] => | legal_UN = [45] => | legal_UN_comment = [46] => | legal_status = [47] => [48] => [49] => | bioavailability = ~60% [50] => | protein_bound = 70–76% [51] => | metabolism = [[Liver]] ([[CYP3A4]], [[CYP1A2]], [[CYP2D6]]) [52] => | metabolites = [53] => | onset = [54] => | elimination_half-life = 5.7 hours [55] => | duration_of_action = [56] => | excretion = [[Kidney]] [57] => [58] => [59] => | CAS_number_Ref = {{cascite|correct|??}} [60] => | CAS_number = 99614-02-5 [61] => | CAS_supplemental = [62] => | PubChem = 4595 [63] => | IUPHAR_ligand = 2290 [64] => | DrugBank_Ref = {{drugbankcite|correct|drugbank}} [65] => | DrugBank = DB00904 [66] => | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} [67] => | ChemSpiderID = 4434 [68] => | UNII_Ref = {{fdacite|correct|FDA}} [69] => | UNII = 4AF302ESOS [70] => | KEGG_Ref = {{keggcite|correct|kegg}} [71] => | KEGG = D00456 [72] => | ChEBI_Ref = [73] => | ChEBI = [74] => | ChEMBL_Ref = {{ebicite|correct|EBI}} [75] => | ChEMBL = 46 [76] => | NIAID_ChemDB = [77] => | PDB_ligand = [78] => | synonyms = [79] => [80] => [81] => | IUPAC_name = (''RS'')-9-Methyl-3-[(2-methyl-1''H''-imidazol-1-yl)methyl]-2,3-dihydro-1''H''-carbazol-4(9''H'')-one [82] => | C=18 | H=19 | N=3 | O=1 [83] => | SMILES = O=C1c2c3ccccc3n(C)c2CCC1Cn4ccnc4C [84] => | StdInChI_Ref = {{stdinchicite|correct|chemspider}} [85] => | StdInChI = 1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3 [86] => | StdInChI_comment = [87] => | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} [88] => | StdInChIKey = FELGMEQIXOGIFQ-UHFFFAOYSA-N [89] => }} [90] => [91] => '''Ondansetron''', sold under the brand name '''Zofran''' among others, is a medication used to prevent [[nausea]] and [[vomiting]] caused by [[Chemotherapy|cancer chemotherapy]], [[radiation therapy]], [[Migraine|migraines]] or surgery. It is also effective for treating [[gastroenteritis]].{{cite journal | vauthors = Schnadower D, Finkelstein Y, Freedman SB | title = Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries | journal = Current Opinion in Gastroenterology | volume = 31 | issue = 1 | pages = 1–6 | date = January 2015 | pmid = 25333367 | doi = 10.1097/mog.0000000000000132 | s2cid = 9334264 }}{{cite journal | vauthors = Freedman SB, Ali S, Oleszczuk M, Gouin S, Hartling L | title = Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries | journal = Evidence-Based Child Health | volume = 8 | issue = 4 | pages = 1123–37 | date = July 2013 | pmid = 23877938 | doi = 10.1002/ebch.1932 }} It can be given [[Oral administration|orally]] (by mouth), [[intramuscular|intramuscularly]] (injection into a muscle), or [[intravenously]] (injection into a vein).{{cite web|title=Ondansetron Hydrochloride|url=https://www.drugs.com/monograph/ondansetron-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|access-date=11 February 2017|archive-url=https://web.archive.org/web/20160503132329/https://www.drugs.com/monograph/ondansetron-hydrochloride.html|archive-date=3 May 2016|url-status=live}} [92] => [93] => [94] => Common [[side effect]]s include [[diarrhea]], [[constipation]], [[headache]], [[sleepiness]], and [[itchiness]]. Serious side effects include [[QT prolongation]] and [[anaphylaxis|severe allergic reaction]]. It appears to be safe during [[pregnancy]] but has not been well studied in this group. It is a [[serotonin]] [[5-HT3 antagonist|5-HT3 receptor antagonist]]. It does not have any effect on [[dopamine receptors]] or [[muscarinic acetylcholine receptor]]s.{{cite book| veditors = Miloro M |title=Peterson's principles of oral and maxillofacial surgery.|date=2012|publisher=People's Medical Pub. House-USA|location=Shelton, CT|isbn=978-1-60795-111-7|page=86|edition=3rd|url=https://books.google.com/books?id=Gxo8AwAAQBAJ&pg=PA86|url-status=live|archive-url=https://web.archive.org/web/20160201173938/https://books.google.ca/books?id=Gxo8AwAAQBAJ&pg=PA86|archive-date=1 February 2016}} [95] => [96] => [97] => Ondansetron was patented in 1984 and approved for medical use in 1990.{{cite book |vauthors=FischerJ, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=448 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA448 |access-date=25 August 2020 |archive-date=12 January 2023 |archive-url=https://web.archive.org/web/20230112141709/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA448 |url-status=live }} It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }} It is available as a [[generic medication]]. In 2021, it was the 79th most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}{{cite web | title = Ondansetron - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Ondansetron | access-date = 14 January 2024}} [98] => [99] => ==Medical uses== [100] => Ondansetron is [[indicated]] for the prevention of [[chemotherapy-induced nausea and vomiting]] and [[postoperative nausea and vomiting]].{{cite web | title=Ondansetron hydrochloride injection | website=DailyMed | date=19 October 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59c4227a-90b6-4297-aacd-05bd097010c1 | access-date=8 July 2023 | archive-date=8 July 2023 | archive-url=https://web.archive.org/web/20230708173847/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59c4227a-90b6-4297-aacd-05bd097010c1 | url-status=live }} [101] => [102] => ===Pregnancy=== [103] => Ondansetron is used [[off-label]] to treat [[morning sickness]] and [[hyperemesis gravidarum]] of [[pregnancy]]. It is typically used after other antinausea drugs have failed.{{cite web | vauthors = Smith JA, Refuerzo JS, Ramin SM | publisher = UpToDate | title = Treatment and outcome of nausea and vomiting of pregnancy | url = https://www.uptodate.com/contents/nausea-and-vomiting-of-pregnancy-treatment-and-outcome | url-status = live | archive-url = https://web.archive.org/web/20131203014208/http://www.uptodate.com/contents/treatment-and-outcome-of-nausea-and-vomiting-of-pregnancy | archive-date = 3 December 2013 }} [104] => [105] => A large multi-center cohort study found no association between ondansetron exposure and fetal risk compared to other antiemetic drugs. {{cite journal | vauthors = Dormuth CR, Winquist B, Fisher A, et al. | title = Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort | journal = JAMA Netw Open | date = April 2021 | volume = 4 | issue = 4 | pages = e215329 | doi = 10.1001/jamanetworkopen.2021.5329| pmid = 33890993 | pmc = 8065380 | doi-access = free }} [106] => [107] => ===Cyclic vomiting syndrome=== [108] => Ondansetron is one of several antiemetic drugs used during the vomiting phase of [[cyclic vomiting syndrome]].{{cite journal | vauthors = Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, Fleisher DR, Hasler WL, Hyman PE, Issenman RM, Li BU, Linder SL, Mayer EA, McCallum RW, Olden K, Parkman HP, Rudolph CD, Taché Y, Tarbell S, Vakil N | display-authors = 6 | title = Cyclic vomiting syndrome in adults | journal = Neurogastroenterology and Motility | volume = 20 | issue = 4 | pages = 269–84 | date = April 2008 | pmid = 18371009 | doi = 10.1111/j.1365-2982.2008.01113.x | url = https://deepblue.lib.umich.edu/bitstream/2027.42/72300/1/j.1365-2982.2008.01113.x.pdf | hdl = 2027.42/72300 | s2cid = 8718836 | doi-access = free | access-date = 4 November 2018 | archive-date = 28 August 2021 | archive-url = https://web.archive.org/web/20210828195918/https://deepblue.lib.umich.edu/bitstream/handle/2027.42/72300/j.1365-2982.2008.01113.x.pdf;jsessionid=96361A3B422890FD8DAE4512F0E07713?sequence=1 | url-status = live }} [109] => [110] => ===Gastroenteritis=== [111] => Trials in emergency department settings support the use of ondansetron to reduce vomiting associated with [[gastroenteritis]] and dehydration.{{cite journal | vauthors = Freedman SB, Adler M, Seshadri R, Powell EC | title = Oral ondansetron for gastroenteritis in a pediatric emergency department | journal = The New England Journal of Medicine | volume = 354 | issue = 16 | pages = 1698–705 | date = April 2006 | pmid = 16625009 | doi = 10.1056/NEJMoa055119 | doi-access=free | s2cid = 13712069 }} A retrospective review found it was used commonly for this purpose, being administered in over 58% of cases. Its use reduced hospital admissions, but was also associated with higher rates of return visits to the emergency department. Furthermore, people who had initially received ondansetron were more likely to be admitted on the return visit than people who had not received the drug. However, this effect may simply be due to the agent being used more frequently in people who present with more severe illness. Its use was not found to mask serious diagnoses.{{cite journal | vauthors = Sturm JJ, Hirsh DA, Schweickert A, Massey R, Simon HK | title = Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses? | journal = Annals of Emergency Medicine | volume = 55 | issue = 5 | pages = 415–22 | date = May 2010 | pmid = 20031265 | doi = 10.1016/j.annemergmed.2009.11.011 }} [112] => [113] => === Irritable bowel syndrome (IBS) === [114] => In a study of patients diagnosed as having IBS with diarrhea (IBS-D), ondansetron showed statistically significant effects on stool consistency, frequency, urgency and bloating, but not on pain scores.{{cite journal | vauthors = Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, Henry A, Hall I, Whorwell P, Spiller R | display-authors = 6 | title = A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea | journal = Gut | volume = 63 | issue = 10 | pages = 1617–1625 | date = October 2014 | pmid = 24334242 | doi = 10.1136/gutjnl-2013-305989 | pmc = 4173656 }} This was confirmed in a later trial and meta-analysis{{cite journal | vauthors = Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, Corsetti M, Scott M, Farmer A, Kapur K, Sanders D, Eugenicos M, Trudgill N, Whorwell P, Mclaughlin J, Akbar A, Houghton L, Dinning PG, Aziz Q, Ford AC, Farrin AJ, Spiller R | title = Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial | journal = Alimentary Pharmacology & Therapeutics | volume = 57 | issue = 11 | pages = 1258–1271 | date = June 2023 | pmid = 36866724 | doi = 10.1111/apt.17426 | url = }} and is included in international guidelines.{{cite journal | vauthors = Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrén M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G | title = Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility | journal = United European Gastroenterology Journal | volume = 10 | issue = 6 | pages = 556–584 | date = July 2022 | pmid = 35695704 | pmc = 9278595 | doi = 10.1002/ueg2.12259 | url = }} [115] => [116] => ==Special populations== [117] => [118] => ===Children=== [119] => Ondansetron has rarely been studied in people under 4 years of age. As such, little data is available to guide dosage recommendations. [120] => [121] => Three open non-comparative studies have been conducted to assess the safety and efficacy of ondansetron in children receiving a variety of chemotherapy regimens. [122] => [123] => Ondansetron was well tolerated and none of the patients experienced extrapyramidal symptoms.{{Cite journal |last=Stevens |first=R F |date=1 January 1991 |title=The role of ondansetron in paediatric patients: a review of three studies |url=https://europepmc.org/article/med/1831631 |journal=European Journal of Cancer |volume=27 |issue=Suppl 1 |pages=S20–2 |issn=1879-0852 |pmid=1831631 |access-date=8 July 2023 |archive-date=8 July 2023 |archive-url=https://web.archive.org/web/20230708132048/https://europepmc.org/article/med/1831631 |url-status=live }} [124] => [125] => ==Adverse effects== [126] => [[Headache]] is the most common [[adverse effect]]. A review of use for post-operative nausea and vomiting found that for every 36 people treated, one would experience headache, which could be severe.{{cite journal | vauthors = Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ | title = Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials | journal = Anesthesiology | volume = 87 | issue = 6 | pages = 1277–89 | date = December 1997 | pmid = 9416710 | doi = 10.1097/00000542-199712000-00004 | s2cid = 8049193 | doi-access = free }} [127] => [128] => [[Constipation]], [[diarrhea]], and [[dizziness]] are other commonly reported side effects. It is broken down by the [[liver|hepatic]] [[cytochrome P450]] system and it has little effect on the [[metabolism]] of other drugs broken down by this system. Anecdotally, [[ototoxicity]] has also been reported if injected too quickly. [129] => [130] => ===QT prolongation=== [131] => Use of ondansetron has been associated with prolongation of the [[QT interval]], which can lead to a potentially fatal heart rhythm known as ''[[torsades de pointes]]''. Although this may happen in any person with any formulation, the risk is most salient with the injectable (intravenous) form of the drug and increases with dose. The risk is also higher in people taking other medicines that prolong the QT interval, as well as in people with [[Long QT syndrome|congenital long QT syndrome]], [[Heart failure|congestive heart failure]], and/or [[Bradycardia|bradyarrhythmias]]. As such, single doses of injectable ondansetron should not exceed 16 mg at one time. (Oral dosing recommendations remain intact, including the recommendation of a single 24 mg oral dose when indicated.) Electrolyte imbalances should be corrected before the use of injectable ondansetron. People are cautioned to seek immediate medical care if symptoms such as irregular heartbeat/palpitations, shortness of breath, dizziness, or fainting occur while taking ondansetron.US Food and Drug Administration. (2012). FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). Retrieved from {{cite web |url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-information-regarding-qt-prolongation-ondansetron-zofran |title=FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran) |website=[[Food and Drug Administration]] |access-date=29 November 2012 |url-status=live |archive-url=https://web.archive.org/web/20121214021055/https://www.fda.gov/Drugs/DrugSafety/ucm310190.htm |archive-date=14 December 2012 }} [132] => [133] => ===Overdose=== [134] => No specific treatment is available for ondansetron overdose; people are managed with supportive measures. An antidote to ondansetron is not known.{{cite web | title=Zofran- ondansetron hydrochloride tablet, film coated | website=DailyMed | date=24 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=555f81bc-4ce0-4f77-b394-b974838c4440 | access-date=7 September 2020 | archive-date=6 August 2020 | archive-url=https://web.archive.org/web/20200806135119/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=555f81bc-4ce0-4f77-b394-b974838c4440 | url-status=live }} [135] => [136] => ==Pharmacology== [137] => [138] => ===Pharmacodynamics=== [139] => Ondansetron is a highly [[binding selectivity|selective]] [[5-HT3 receptor|serotonin 5-HT3 receptor]] [[receptor antagonist|antagonist]], with low [[affinity (pharmacology)|affinity]] for [[dopamine receptor]]s. The 5-HT3 receptors are present both [[periphery (body)|peripherally]] on [[vagus nerve|vagal nerve]] terminals and centrally in the [[chemoreceptor trigger zone]] of the [[area postrema]] in the [[medulla oblongata|medulla]]. Serotonin is released by the [[enterochromaffin cell]]s of the [[small intestine]] in response to [[chemotherapeutic agent]]s and may stimulate vagal [[afferent nerve fiber|afferent]]s (via 5-HT3 receptors) to initiate the [[vomiting reflex]]. It is thought that ondansetron's antiemetic action is mediated mostly via antagonism of vagal afferents with a minor contribution from antagonism of [[central nervous system|central]] receptors.{{cite journal | vauthors = Browning KN | title = Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology | journal = Frontiers in Neuroscience | volume = 9 | pages = 413 | date = October 2015 | pmid = 26578870 | pmc = 4625078 | doi = 10.3389/fnins.2015.00413 | doi-access = free }} [140] => [141] => ===Pharmacokinetics=== [142] => Ondansetron may have a degree of [[peripherally selective drug|peripheral selectivity]] due to binding to [[P-glycoprotein]] and efflux out of the brain at the [[blood–brain barrier]].{{cite journal | vauthors = Schinkel AH, Wagenaar E, Mol CA, van Deemter L | title = P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs | journal = Journal of Clinical Investigation| volume = 97 | issue = 11 | pages = 2517–24 | date = June 1996 | pmid = 8647944 | pmc = 507337 | doi = 10.1172/JCI118699 | url = }}{{cite journal | vauthors = Kwan C, Bédard D, Frouni I, Gaudette F, Beaudry F, Hamadjida A, Huot P | title = Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat | journal = Canadian Journal of Physiology and Pharmacology| volume = 98 | issue = 7 | pages = 431–440 | date = July 2020 | pmid = 32017606 | doi = 10.1139/cjpp-2019-0551 | s2cid = 211035717 | url = }}{{cite journal | vauthors = Scott JA, Wood M, Flood P | title = The pronociceptive effect of ondansetron in the setting of P-glycoprotein inhibition | journal = Anesthesia & Analgesia| volume = 103 | issue = 3 | pages = 742–6 | date = September 2006 | pmid = 16931690 | doi = 10.1213/01.ane.0000228861.80314.22 | s2cid = 44405604 | url = | doi-access = free }} [143] => [144] => ==History== [145] => [[File:Ondansetron (1).JPG|thumb|right|A vial of Zofran 4 mg containing ondansetron for intravenous injection]] [146] => [147] => Ondansetron (marketed under the brand name Zofran) was developed in the mid-1980s by [[GlaxoSmithKline]] in London. It was granted US patent protection in September 1987,{{ cite patent | country = US | number = 4695578 | status =patent | title = 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances | gdate = 22 September 1987 | fdate = 17 November 1986 | inventor = Coates IH, Bell JA, Humber DC, Ewan GB | assign1 = Glaxo Group Limited }} received a use patent June 1988,{{ cite patent | country = US | number = 4753789 | status =patent | title = Method for treating nausea and vomiting | gdate = 28 June 1988 | fdate = 24 June 1986 | inventor = Tyers MB, Coates IH, Humber DC, Ewan GB, Bell JA | assign1 = Glaxo Group Limited }} and was approved by the US FDA in January 1991. It was granted another divisional patent in November 1996.{{ cite patent | country = US | number = 5578628 | status =patent | title = Medicaments for the treatment of nausea and vomiting | gdate = 26 November 1996 | fdate = 30 March 1990 | inventor = Tyers MB, Coates IH, Humber DC, Ewan GB, Bell JA | assign1 = Glaxo Group Limited }} Finally, owing to GlaxoSmithKline's research on pediatric use, ondansetron's patent protection was extended until December 2006.{{cite web | url = https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_06_03_OndansetronUseReview%20Cleared.pdf | title = One Year Post-Pediatric Exclusivity Post-marketing Adverse Event Review: Drug Use Data Zofran | date = 7 March 2006 | work = Memorandum | publisher = U.S. Food and Drug Administration | url-status = live | archive-url = https://web.archive.org/web/20150924170611/https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_06_03_OndansetronUseReview%20Cleared.pdf | archive-date = 24 September 2015 }} By this final year of its patent (2006), Zofran had become the 20th highest-selling brand-name drug in the United States, with sales of US$1.3 billion in the first 9 months of 2006 (80% from the US).IHS. (2006). Generics firms line up to enter Zofran market. Retrieved from {{cite web |url=https://ihsmarkit.com/country-industry-forecasting.html?id=106598562 |title=Generics Firms Line Up to Enter Zofran Market |access-date=20 January 2014 |url-status=live |archive-url=https://web.archive.org/web/20140201231754/http://www.ihs.com/products/global-insight/industry-economic-report.aspx?id=106598562 |archive-date=1 February 2014 }} The first generic versions were approved by the US FDA in December 2006, with marketing approval granted to [[Teva Pharmaceutical Industries|Teva Pharmaceuticals USA]] and SICOR Pharmaceuticals.{{cite press release | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108817.htm | title = FDA Approves First Generic Ondansetron Tablets, Orally Disintegrating Tablets and Oral Solution | date = 17 December 2006 | publisher = U.S. Food and Drug Administration | url-status = dead | archive-url = https://web.archive.org/web/20140618211006/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108817.htm | archive-date = 18 June 2014 }} In 2018, [[University of São Paulo]] and Biolab were granted a patent for an [[Orodispersible tablet|orodispersible]] form of the drug.{{Cite web|title=Sabia que um remédio para enjoo traz 90% dos royalties que a USP recebe? - Agência USP de Inovação|url=http://www.inovacao.usp.br/sabia-que-um-remedio-para-enjoo-traz-90-dos-royalties-que-a-usp-recebe/|access-date=6 October 2020|language=pt-BR}} [148] => [149] => ==Society and culture== [150] => [151] => ===Publication bias=== [152] => In 1997, ondansetron was the subject of a [[meta-analysis]] case study published in the ''[[British Medical Journal]]''. Researchers examined 84 trials, with 11,980 people receiving ondansetron, published between 1991 and September 1996. Intravenous ondansetron 4 mg versus placebo was investigated in 16 reports and three further reports which had been duplicated a total of six times. The [[number needed to treat]] (NNT) to prevent vomiting within 24 hours was 9.5, with 95% confidence interval 6.9 to 15, in the 16 nonduplicated reports. In the three duplicated reports, the NNT was significantly lower at 3.9 (3.3 to 4.8). When all 25 reports were combined, the apparent NNT improved to 4.9 (4.4 to 5.6). Inclusion of duplicate reports led to a 23% overestimation of ondansetron's antiemetic efficacy.{{cite journal | vauthors = Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ | title = Impact of covert duplicate publication on meta-analysis: a case study | journal = BMJ | volume = 315 | issue = 7109 | pages = 635–40 | date = September 1997 | pmid = 9310564 | pmc = 2127450 | doi = 10.1136/bmj.315.7109.635 }} [153] => [154] => In addition, the authors found the covert duplication of reports on ondansetron was not easy to detect, because of lack of cross-referencing between papers, and reports containing duplicate findings were cited in eight reviews of the drug. Their analysis was a subject of an editorial in the ''[[Journal of the American Medical Association]]'' in 1999.{{cite journal | vauthors = Rennie D | title = Fair conduct and fair reporting of clinical trials | journal = JAMA | volume = 282 | issue = 18 | pages = 1766–8 | date = November 1999 | pmid = 10568651 | doi = 10.1001/jama.282.18.1766 }} [155] => [156] => ===Availability=== [157] => Ondansetron is a [[generic medication]] and is available in many countries under many brand names.{{cite web | title=Ondansetron international | website=Drugs.com | date=2 September 2020 | url=https://www.drugs.com/international/ondansetron.html | access-date=2 February 2014 | archive-url=https://web.archive.org/web/20140221202123/https://www.drugs.com/international/ondansetron.html |archive-date=21 February 2014 |url-status=live }} [158] => [159] => ==References== [160] => {{Reflist}} [161] => [162] => {{5-HT3 antagonists}} [163] => {{Serotonin receptor modulators}} [164] => {{GlaxoSmithKline}} [165] => {{Portal bar|Medicine}} [166] => [167] => [[Category:Antiemetics]] [168] => [[Category:5-HT3 antagonists]] [169] => [[Category:Imidazoles]] [170] => [[Category:Ketones]] [171] => [[Category:Peripherally selective drugs]] [172] => [[Category:World Health Organization essential medicines]] [173] => [[Category:Wikipedia medicine articles ready to translate]] [] => )
good wiki

Ondansetron

Ondansetron is a medication primarily used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. It belongs to a class of drugs called serotonin 5-HT3 receptor antagonists.

More about us

About

It belongs to a class of drugs called serotonin 5-HT3 receptor antagonists. The Wikipedia page on ondansetron provides a detailed overview of the medication, including its history, mechanism of action, pharmacokinetics, and therapeutic uses. The page explains that ondansetron works by blocking the action of serotonin, a neurotransmitter in the central and peripheral nervous systems that is associated with nausea and vomiting. The page also describes the various forms in which ondansetron is available, including tablets, oral disintegrating tablets, and injectable solutions. It further discusses the recommended dosages for different conditions and patient populations. Additionally, the Wikipedia page covers the potential adverse effects and contraindications of ondansetron. Common side effects include headache, constipation, and dizziness, while rare but severe reactions such as cardiac arrhythmias are also mentioned. The page highlights the importance of monitoring patients with certain medical conditions, such as those with a history of heart disease or electrolyte imbalances. Furthermore, the page provides information on the drug's pharmacokinetics, emphasizing its significant first-pass metabolism and hepatic clearance. It also mentions any interactions with other medications, notably those that affect hepatic metabolism. The Wikipedia page concludes by discussing ongoing research and controversies surrounding ondansetron. It presents the findings of various clinical studies and mentions some debates regarding the drug's effectiveness and potential risks. The page does not provide medical advice and advises readers to consult healthcare professionals for personalized information. Overall, the Wikipedia page on ondansetron serves as a comprehensive resource, offering a thorough overview of the medication's properties, uses, adverse effects, and pharmacokinetics.

Expert Team

Vivamus eget neque lacus. Pellentesque egauris ex.

Award winning agency

Lorem ipsum, dolor sit amet consectetur elitorceat .

10 Year Exp.

Pellen tesque eget, mauris lorem iupsum neque lacus.

You might be interested in

Anaphylaxis

Anaphylaxis is a severe and potentially life-threatening allergic reaction that occurs rapidly and affects multiple body systems.

Chemotherapy

Chemotherapy is a widely used treatment method in the field of oncology, aimed at treating cancer by administering drugs that kill rapidly dividing cells.

CYP3A4

CYP3A4 is an enzyme that belongs to the cytochrome P450 family and is primarily found in the liver.

Kidney

The kidney is an essential organ in the human body responsible for filtering waste products and excess water from the bloodstream, producing urine, and maintaining proper levels of electrolytes and fluids.

Liver

The liver is an organ in the human body located in the upper right abdomen.